Pfizer pulls a trump card in RSV

Posted 25 March 2025 AM

Pfizer has become the second company to register a respiratory syncytial virus (RSV) vaccine in Australia following GSK.

While Pfizer is about three months behind its rival it has a trump card, securing a broader indication for Abrysvo.

To see the whole article, please login

Popular

Latest Jobs

Pharma in Focus Jobs

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now